Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy

Journal of Controlled Release

Volumn 200, Issue , 2015, Pages 201-211

  Ma, Xinpeng ^a   Huang, Xiumei ^a   Moore, Zachary ^a   Huang, Gang ^a   Kilgore, Jessica A ^a   Wang, Yiguang ^a   Hammer, Suntrea ^a   Williams, Noelle S ^a   Boothman, David A ^a   Gao, Jinming ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cancer nanomedicine; Non small cell lung cancer; Polymeric micelles; Prodrug therapy; Lapachone

Indexed keywords

BIOCOMPATIBILITY; BIOLOGICAL ORGANS; CELLS; CYTOLOGY; DISEASES; DRUG PRODUCTS; ENZYMES; ESTERS; LACTIC ACID; LOADING; MEDICAL NANOTECHNOLOGY; ONCOLOGY; POLYETHYLENE GLYCOLS;

ANTI-TUMOR EFFICACY; AREA UNDER THE CONCENTRATION-TIME CURVES; LUNG CANCER THERAPY; NON SMALL CELL LUNG CANCER; POLY (D , L LACTIC ACID); POLYMERIC MICELLE; PRODRUGS; THERAPEUTIC EFFICACY;

MICELLES;

ADENOSINE TRIPHOSPHATE; BETA LAPACHONE; ESTERASE; GAMMA HISTONE H2AX; HISTONE H2AX; MACROGOL; NAD(P)H QUINONE OXIDOREDUCTASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; POLYLACTIC ACID; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BETA-LAPACHONE; LACTIC ACID DERIVATIVE; MACROGOL DERIVATIVE; MICELLE; NANOPARTICLE; NAPHTHOQUINONE; NQO1 PROTEIN, HUMAN; NQO1 PROTEIN, MOUSE; POLY(LACTIC ACID-ETHYLENE GLYCOL);

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CANCER THERAPY; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; FEMALE; H596 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; LD 50; LONG TERM SURVIVAL; LUNG CANCER; LUNG CANCER CELL LINE; MAXIMUM TOLERATED DOSE; MICELLE; MOUSE; NANOENCAPSULATION; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; COMET ASSAY; DRUG EFFECTS; ERYTHROCYTE; HEMOLYSIS; HUMAN; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMET ASSAY; ERYTHROCYTES; ESTERASES; FEMALE; HEMOLYSIS; HUMANS; LACTATES; LUNG NEOPLASMS; MICE, SCID; MICELLES; NAD(P)H DEHYDROGENASE (QUINONE); NANOPARTICLES; NAPHTHOQUINONES; POLYETHYLENE GLYCOLS; PRODRUGS; TUMOR BURDEN;

EID: 84921059226     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.12.027     Document Type: Article

References (47)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J. Clin. 63 2013 11 30
2. D. Ross, and D. Siegel NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics Methods Enzymol. 382 2004 115 144
3. A.K. Jaiswal Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin Biochemistry (Washington) 30 1991 10647 10653
4. D.A. Boothman, M. Meyers, N. Fukunaga, and S.W. Lee Isolation of X-ray-inducible transcripts from radioresistant human melanoma cells Proc. Natl. Acad. Sci. U. S. A. 90 1993 7200 7204
5. D. Ross, J.K. Kepa, S.L. Winski, H.D. Beall, A. Anwar, and D. Siegel NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms Chem. Biol. Interact. 129 2000 77 97
6. A. Marin, A. Lopez de Cerain, E. Hamilton, A.D. Lewis, J.M. Martinez-Penuela, M.A. Idoate, and J. Bello DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours Br. J. Cancer 76 1997 923 929
7. M. Belinsky, and A.K. Jaiswal NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues Cancer Metastasis Rev. 12 1993 103 117
8. M. Ough, A. Lewis, E.A. Bey, J. Gao, J.M. Ritchie, W. Bornmann, D.A. Boothman, L.W. Oberley, and J.J. Cullen Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1 Cancer Biol. Ther. 4 2005 102 109
9. Y. Dong, E.A. Bey, L.-S. Li, W. Kabbani, J. Yan, X.-J. Xie, J.-T. Hsieh, J. Gao, and D.A. Boothman Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation Cancer Res. 70 2010 8088 8096
10. A.S. Prakash, H. Beall, D. Ross, and N.W. Gibson Sequence-selective alkylation and cross-linking induced by mitomycin C upon activation by DT-diaphorase Biochemistry 32 1993 5518 5525
11. D. Siegel, N.W. Gibson, P.C. Preusch, and D. Ross Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells Cancer Res. 50 1990 7483 7489
12. G.K. Rekha, and N.E. Sladek Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics Cancer Chemother. Pharmacol. 40 1997 215 224
13. J.J. Pink, S.M. Planchon, C. Tagliarino, M.E. Varnes, D. Siegel, and D.A. Boothman NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity J. Biol. Chem. 275 2000 5416 5424
14. E.A. Bey, K.E. Reinicke, M.C. Srougi, M. Varnes, V.E. Anderson, J.J. Pink, L.S. Li, M. Patel, L. Cao, Z. Moore, A. Rommel, M. Boatman, C. Lewis, D.M. Euhus, W.G. Bornmann, D.J. Buchsbaum, D.R. Spitz, J. Gao, and D.A. Boothman Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers Mol. Cancer Ther. 12 2013 2110 2120
15. E.A. Bey, M.S. Bentle, K.E. Reinicke, Y. Dong, C.R. Yang, L. Girard, J.D. Minna, W.G. Bornmann, J. Gao, and D.A. Boothman An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone Proc. Natl. Acad. Sci. U. S. A. 104 2007 11832 11837
16. H.T. Khong, L. Dreisbach, H.L. Kindler, D.F. Trent, K.G. Jeziorski, I. Bonderenko, T. Popiela, D.M. Yagovane, and G. Dombal A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma J. Clin. Oncol. (Meeting Abstracts) 25 2007 15017
17. L. Hartner, L. Rosen, M. Hensley, D. Mendelson, A. Staddon, W. Chow, O. Kovalyov, W. Ruka, K. Skladowski, A. Jagiello-Gruszfeld, and M. Byakhov Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS) J. Clin. Oncol. (Meeting Abstracts) 25 2007 20521
18. N. Nasongkla, A. Wiedmann, A. Bruening, M. Beman, D. Ray, W. Bornmann, D. Boothman, and J. Gao Enhancement of solubility and bioavailability of β-lapachone using cyclodextrin inclusion complexes Pharm. Res. 20 2003 1626 1633
19. E. Blanco, E.A. Bey, C. Khemtong, S.-G. Yang, J. Setti-Guthi, H. Chen, C.W. Kessinger, K.A. Carnevale, W.G. Bornmann, D.A. Boothman, and J. Gao β-Lapachone micellar nanotherapeutics for non-small cell lung cancer therapy Cancer Res. 70 2010 3896 3904
20. E. Blanco, E.A. Bey, Y. Dong, B.D. Weinberg, D.M. Sutton, D.A. Boothman, and J. Gao β-Lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells J. Control. Release 122 2007 365 374
21. V.P. Torchilin Structure and design of polymeric surfactant-based drug delivery systems J. Control. Release 73 2001 137 172
22. R. Gref, Y. Minamitake, M. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer Biodegradable long-circulating polymeric nanospheres Science 263 1994 1600 1603
23. H. Hashizume, P. Baluk, S. Morikawa, J.W. McLean, G. Thurston, S. Roberge, R.K. Jain, and D.M. McDonald Openings between defective endothelial cells explain tumor vessel leakiness Am. J. Pathol. 156 2000 1363 1380
24. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzym. Regul. 41 2001 189 207
25. X. Ma, X. Huang, G. Huang, L. Li, Y. Wang, X. Luo, D.A. Boothman, and J. Gao Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-lapachone Adv. Healthc. Mater. 3 2014 1210 1216
26. Z. Moore, G. Chakrabarti, X. Lou, A. Ali, R. Deberadinis, R. Brekken, and D.A. Boothman NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by ß-lapachone Cell Death Dis. 2015 (in press)
27. S.M. Planchon, S. Wuerzberger, B. Frydman, D.T. Witiak, P. Hutson, D.R. Church, G. Wilding, and D.A. Boothman β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: A p53-independent response Cancer Res. 55 1995 3706 3711
28. M.S. Bentle, K.E. Reinicke, E.A. Bey, D.R. Spitz, and D.A. Boothman Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair J. Biol. Chem. 281 2006 33684 33696
29. J.J. Pink, S.M. Planchon, C. Tagliarino, S.M. Wuerzberger-Davis, M.E. Varnes, D. Siegel, and D.A. Boothman NAD(P)H:quinone oxidoreductase (NQO1) activity is the principal determinant of ß-lapachone cytotoxicity J. Biol. Chem. 275 2000 5416 5424
30. C. Labarca, and K. Paigen A simple, rapid, and sensitive DNA assay procedure Anal. Biochem. 102 1980 344 352
31. P.L. Olive, J.P. Banáth, and R.E. Durand Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay Radiat. Res. 122 1990 86 94
32. X. Huang, Y. Dong, E.A. Bey, J.A. Kilgore, J.S. Bair, L.-S. Li, M. Patel, E.I. Parkinson, Y. Wang, N.S. Williams, J. Gao, P.J. Hergenrother, and D.A. Boothman An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis Cancer Res. 72 2012 3038 3047
33. M.K. Ross, and J.A. Crow Human carboxylesterases and their role in xenobiotic and endobiotic metabolism J. Biochem. Mol. Toxicol. 21 2007 187 196
34. G. Xu, W. Zhang, M.K. Ma, and H.L. McLeod Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan Clin. Cancer Res. 8 2002 2605 2611
35. X. Lu, M.D. Howard, D.R. Talbert, J.J. Rinehart, P.M. Potter, M. Jay, and M. Leggas Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release AAPS J. 11 2009 120 122
36. Y. Shen, E. Jin, B. Zhang, C.J. Murphy, M. Sui, J. Zhao, J. Wang, J. Tang, M. Fan, E. Van Kirk, and W.J. Murdoch Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery J. Am. Chem. Soc. 132 2010 4259 4265
37. A. Kawecki, D.R. Adkins, C.C. Cunningham, E. Vokes, D.M. Yagovane, G. Dombal, P. Koralewski, Y. Hotko, and V. Vladimirov A phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck J. Clin. Oncol. (Meeting Abstracts) 25 2007 16509
38. R.L. Hartner PL, M. Hensley, D. Mendelson, A.P. Staddon, W. Chow, O. Kovalyov, W. Ruka, K. Skladowski, A. Jagiello-Gruszfeld, and M. Byakhov Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS) J. Clin. Oncol. 25 2007
39. K.E. Reinicke, E.A. Bey, M.S. Bentle, J.J. Pink, S.T. Ingalls, C.L. Hoppel, R.I. Misico, G.M. Arzac, G. Burton, W.G. Bornmann, D. Sutton, J. Gao, and D.A. Boothman Development of β-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels Clin. Cancer Res. 11 2005 3055 3064
40. J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Jarvinen, and J. Savolainen Prodrugs: design and clinical applications Nat. Rev. Drug Discov. 7 2008 255 270
41. C.E. Müller Prodrug approaches for enhancing the bioavailability of drugs with low solubility Chem. Biodivers. 6 2009 2071 2083
42. S. Samarajeewa, R. Shrestha, Y. Li, and K.L. Wooley Degradability of poly(lactic acid)-containing nanoparticles: enzymatic access through a cross-linked shell barrier J. Am. Chem. Soc. 134 2012 1235 1242
43. N. Cenas, and K. Ollinger Redox conversions of methemoglobin during redox cycling of quinones and aromatic nitrocompounds Arch. Biochem. Biophys. 315 1994 170 176
44. D.A. Boothman, D.K. Trask, and A.B. Pardee Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I Cancer Res. 49 1989 605 612
45. C.J. Li, Y.-Z. Li, A.V. Pinto, and A.B. Pardee Potent inhibition of tumor survival in vivo by β-lapachone plus taxol: combining drugs imposes different artificial checkpoints Proc. Natl. Acad. Sci. U. S. A. 96 1999 13369 13374
46. A. D'Anneo, G. Augello, A. Santulli, M. Giuliano, R. di Fiore, C. Messina, G. Tesoriere, and R. Vento Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt J. Cell. Physiol. 222 2010 433 443
47. H. Kim, C. Rigell, G. Zhai, S.K. Lee, S. Samuel, A. Martin, H. Umphrey, C. Stockard, T.M. Beasley, D. Buchsbaum, L. Li, D. Boothman, and K. Zinn Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers Mol. Imaging Biol. 16 2014 85 94